WJPPS Citation

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • New Impact Factor
  • WJPPS Impact Factor has been Increased to 8.025 for Year 2024.

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Scope Indexed
  • WJPPS is indexed in Scope Database based on the recommendation of the Content Selection Committee (CSC).

  • WJPPS: NOVEMBER ISSUE PUBLISHED
  • NOVEMBER 2025 Issue has been successfully launched on 1 NOVEMBER 2025.

Abstract

IMPACT OF IMMUNOTHERAPY ON PHARMACOLOGICAL TREATMENT OF AUTOIMMUNE DISEASE

Ujwal Pramod Wankhede*, Gaurav Umesh Patil, Pushkar Namdeo Marathe, Sahil Sanjay Mali and Jitendra More

ABSTRACT

Immunotherapy is a revolutionary strategy in the treatment of autoimmune diseases, consisting on modifying or restoring immunity to recover immune balance and suppress disease activity. In the present study, systematic research was carried out with an objective to assess how effective and safe immunotherapy is in general as well as its overall impact on pharmacological treatment of autoimmune disorders. A systematic search was done across multiple databases which were PubMed, Scopus and Clinical Trials gov, and identified studies from 2010 to April 24th, 2024. Study design and data collection We included clinical trials or observational studies that enrolled adults with autoimmune diseases, describing treatment effects outcomes (efficacy), quality of life (QoL); safety profiles; mechanistic pathways of immunotherapy. There was a total of 85 studies representing 5,600 patients that made up the analysis. An overall response rate of 68% to immunotherapy was also found, paired with substantial reductions in disease activity scores for rheumatoid arthritis and systemic lupus erythematosus among other conditions. Similarly, changes from baseline in physical and mental health scores also showed the therapeutic benefit of immunotherapy with respect to quality of life. While 30% of patients had treatment-related adverse events, most were easily managed and serious adverse events occurred in about only 5%. A biomarker study confirmed changes in inflammatory cytokines and regulatory T cells, suggesting the beneficial effects of immunotherapy. The results further support immuno-therapy as a potential treatment option with meaningful clinical efficacy and acceptable safety for autoimmune diseases. Further research exploring optimized treatment protocols as well as potentially synergistic combination therapies that improve therapeutic efficacy, are needed in the future.

Keywords: Immunotherapy, Autoimmune diseases, Efficacy, Safety, Quality of life, Pharmacological treatment, Cytokines, Regulatory T cells.


[Download Article]     [Download Certifiate]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More